Physician profile
Barbara A Wright-Bruce
NPI 1437123924
$3,494.26
in general payments reported to CMS, 2019-2025
24 companies · $743 in 2025
The $743 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $620 · 2022: $452 · 2023: $619 · 2024: $1,060 · 2025: $743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,422.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,422.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $824.03 | 2021-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $612.34 | 2022-2025 | Airsupra, Farxiga, Lokelma |
| Abbvie INC. | $466.16 | 2022-2025 | |
| Exact Sciences Corporation | $309.12 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $186.09 | 2024-2025 | Repatha, Otezla, Otezla |
| Xeris Pharmaceuticals, INC. | $120.92 | 2021-2024 | Gvoke Hypopen |
| Lilly USA, LLC | $115.87 | 2021-2024 | Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $83.33 | 2021 | |
| Novartis Pharmaceuticals Corporation | $78.81 | 2021-2024 | |
| Viiv Healthcare Company | $72.12 | 2024-2025 | Apretude |
| Indivior INC. | $69.61 | 2022-2024 | Sublocade |
| Pfizer INC. | $65.89 | 2022-2025 | |
| Dexcom, INC. | $61.08 | 2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $60.87 | 2024-2025 | |
| Abbott Laboratories | $58.52 | 2021-2023 | Freestyle Libre 3 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $56.85 | 2023-2025 | Vivitrol, Vivitrol |
| Corcept Therapeutics | $45.72 | 2025 | Korlym |
| Amarin Pharma, INC. | $38.74 | 2021 | |
| Sumitomo Pharma America, INC. | $31.59 | 2023 | Gemtesa |
| Scynexis, INC. | $31.40 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.85 | 2022-2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $29.43 | 2025 | Caplyta |
| Acadia Pharmaceuticals INC | $26.79 | 2025 | Nuplazid |
| Otsuka America Pharmaceutical, INC. | $19.13 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Wright-Bruce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.